Nicotinamide adenine dinucleotide (NAD+) sits at the intersection of energy metabolism, DNA repair, and cellular signaling. This article reviews what preclinical and human research reports about NAD+ biology and the enzymes that depend on it, and states plainly where the evidence is strong and where it is not.

What NAD+ is and why its levels matter

NAD+ is a small dinucleotide that participates in hundreds of biochemical reactions. In its classical role it shuttles electrons between the oxidized (NAD+) and reduced (NADH) forms, driving glycolysis, the tricarboxylic acid cycle, fatty-acid oxidation, and oxidative phosphorylation.² This redox function is why the molecule is often described as central to energy metabolism.

A second, non-redox role has drawn most of the attention in aging research. NAD+ is also consumed as a substrate by several enzyme classes that cleave the molecule to carry out signaling reactions. Because these enzymes physically degrade NAD+ rather than recycle it, the cell must continuously resynthesize the cofactor, principally through the salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT).² The balance between biosynthesis and consumption sets the intracellular NAD+ concentration at any moment.³

Multiple model organisms, from Caenorhabditis elegans to rodents and humans, show a gradual decline in tissue NAD+ with age.¹ Reviews attribute this decline to a shifting equilibrium: reduced NAMPT expression on the biosynthetic side, and increased activation of NAD+-consuming enzymes such as PARPs and CD38 on the consumption side.³ The correlation between falling NAD+ and age-associated cellular changes is what motivates the experimental interest; it is a correlation and a mechanistic hypothesis, not a demonstrated causal chain in humans.

The NAD+-consuming enzymes: sirtuins, PARPs, CD38

Three enzyme families dominate the non-redox use of NAD+, and each links the cofactor to a distinct biological process.¹

Sirtuins

Sirtuins (SIRT1–7) are NAD+-dependent deacylases. They remove acetyl and other acyl groups from histones and non-histone proteins, using NAD+ as an obligatory co-substrate in the reaction. Through this activity, sirtuins are studied in the context of chromatin remodeling, mitochondrial regulation, and transcriptional control.¹ Because the reaction requires NAD+, sirtuin output is sensitive to the ambient NAD+ concentration, which is the mechanistic basis for linking NAD+ decline to reduced sirtuin signaling.⁶

Poly(ADP-ribose) polymerases (PARPs)

PARPs, of which PARP1 is the most abundant, were first identified as DNA-damage-response proteins. On detecting strand breaks, PARP1 consumes NAD+ to build poly(ADP-ribose) chains on target proteins, marking sites of damage and recruiting repair machinery.⁴ Intense PARP activation during genotoxic stress can draw down the nuclear NAD+ pool substantially, which is one proposed route by which DNA damage and NAD+-dependent signaling become coupled.⁵

CD38 and CD157 ectoenzymes

CD38 and its relative CD157 (BST1) hydrolyze NAD+ to generate calcium-mobilizing second messengers such as cyclic ADP-ribose. CD38 is expressed on immune cells and has been reported to increase with age, positioning it as a major NAD+ consumer that ties the cofactor to calcium signaling, immune communication, and inflammatory processes.⁷ Because sirtuins and PARPs compete for the same finite NAD+ pool, researchers describe an interplay in which the activity of one family can influence substrate availability for the others.⁴

NAD+ and DNA damage repair

The connection between NAD+ and genomic maintenance runs primarily through PARP-dependent repair. When oxidative or alkylation damage produces single-strand breaks, PARP1 rapidly synthesizes ADP-ribose polymers that scaffold the base excision repair apparatus.⁴ Each ADP-ribose unit is derived from an NAD+ molecule, so sustained repair activity is metabolically expensive in NAD+ terms.

Preclinical work has proposed a feedback relationship between NAD+ status and repair capacity. In aged mice, one model describes an inhibitory NAD+-binding protein (DBC1) forming a complex with PARP1 when NAD+ is low, dampening PARP catalytic activity; raising NAD+ with the precursor nicotinamide mononucleotide dissociated this complex and restored PARP activity toward youthful levels in that system.⁵ Separately, studies in DNA-repair-deficient models such as Cockayne syndrome have linked nuclear NAD+ depletion by PARP to secondary loss of sirtuin (SIRT1) function and mitochondrial defects, effects that were attenuated by increasing NAD+.⁶

These are rodent and cellular findings. They establish a plausible mechanism by which NAD+ availability supports the enzymatic machinery of repair, but they do not establish that supplementing NAD+ improves genomic stability in healthy humans. The review literature is explicit that prolonged disequilibrium of NAD+ metabolism disturbs physiological function; it stops short of claiming that repletion reverses those disturbances in people.²

Cellular aging processes linked to NAD+

Beyond DNA repair, NAD+-dependent enzymes touch several processes that recur in aging biology. The three below are the most frequently examined in the mechanistic literature.¹

Mitochondrial function and energy balance

As the electron carrier for oxidative phosphorylation and a co-substrate for mitochondrial sirtuins (SIRT3–5), NAD+ is tied to mitochondrial output and quality control. In preclinical models, restoring NAD+ has been associated with improved mitochondrial function and, through sirtuin signaling, with the mitochondrial unfolded protein response.⁵ Whether these effects translate to bioenergetic gains in human tissue is uncertain: a controlled human trial that raised muscle NAD+ with a precursor found transcriptomic changes but no measurable change in mitochondrial bioenergetics.¹⁰

Inflammation and immune regulation

NAD+ metabolism intersects with immune signaling through CD38 and through sirtuin-mediated control of inflammatory transcription.⁷ In aged human skeletal muscle, precursor supplementation lowered circulating inflammatory cytokines, one of the more reproducible functional signals reported to date.¹⁰ Peptides studied for mitochondrial and metabolic signaling, such as MOTS-C, are sometimes examined alongside NAD+ biology in the same experimental framing, though they act through distinct pathways.

Genomic stability and cellular senescence

Through the combined activity of sirtuins and PARPs, NAD+ influences chromatin structure and the DNA-damage response, both of which feed into whether a stressed cell enters senescence.¹ The NAD+/PARP1/SIRT1 axis has been proposed as a node connecting NAD+ levels, accumulated DNA damage, and epigenetic "clock" measures of biological age, but this remains a hypothesis under active investigation rather than an established mechanism.⁵

What human clinical studies actually show

An important distinction: the product context here is NAD+ itself, but the human clinical record is dominated by NAD+ precursors—nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)—which the body converts to NAD+. Direct NAD+ administration in controlled human trials is comparatively sparse. What the precursor trials establish clearly is pharmacological: oral precursors raise blood and tissue NAD+ in a dose-dependent, well-tolerated manner.⁸⁹

The functional outcomes are where results diverge. Trials have reported anti-inflammatory signatures and signals toward lower blood pressure and arterial stiffness in older adults,⁹¹⁰ and a randomized, placebo-controlled trial found improved muscle insulin sensitivity in prediabetic women given NMN.¹¹ Yet a cognition trial in older adults with mild cognitive impairment raised blood NAD+ 2.6-fold without changing cognitive scores,¹³ and an early Parkinson's trial found cerebral NAD+ rose only variably across participants.¹² The consistent message is that raising NAD+ is achievable and well tolerated over the durations tested; producing a defined clinical benefit is not consistently demonstrated.

Across these studies, no trial measured lifespan or demonstrated reversal of aging. Reviewers repeatedly call for larger, longer, mechanistically targeted trials to determine which populations, if any, derive a durable functional benefit.¹³

Evidence level and regulatory status

The mechanistic case for NAD+ in cellular repair and aging biology rests on a strong body of in vitro and rodent work supported by a smaller set of human precursor trials that confirm target engagement (NAD+ elevation) but yield mixed functional results. The strongest claims—improved DNA repair, delayed senescence, extended healthspan—remain preclinical or hypothesis-stage in humans. Direct administration of NAD+ itself, as opposed to its precursors, has limited controlled human data.

Considerations for laboratory research

For investigators modeling NAD+ biology in vitro or in preclinical systems, compound identity and consistency directly affect reproducibility. NAD+ studies frequently turn on the ratio between the oxidized and reduced forms and on precise intracellular concentrations, so batch-to-batch variability in the starting material can confound mechanistic readouts of sirtuin, PARP, or CD38 activity. Well-characterized, analytically documented materials help keep experimental variance attributable to the biology rather than the reagent. Qovigen supplies research-grade NAD+ (500 mg) for this purpose, intended solely for laboratory investigation.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.